Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC decreased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 1.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 239,868 shares of the specialty pharmaceutical company's stock after selling 3,137 shares during the quarter. Wedge Capital Management L L P NC owned 0.39% of Jazz Pharmaceuticals worth $29,780,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. LSV Asset Management increased its position in shares of Jazz Pharmaceuticals by 1.5% in the 4th quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock valued at $311,699,000 after purchasing an additional 37,108 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after buying an additional 320,724 shares during the last quarter. Capital World Investors raised its stake in Jazz Pharmaceuticals by 5.7% in the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock valued at $236,860,000 after buying an additional 104,195 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after buying an additional 315,608 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Jazz Pharmaceuticals by 4.8% during the 4th quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock worth $195,506,000 after acquiring an additional 72,007 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,140 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at approximately $966,323.72. The trade was a 13.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Seamus Mulligan bought 100,000 shares of the business's stock in a transaction dated Friday, May 9th. The shares were acquired at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the purchase, the director now owns 100,000 shares in the company, valued at approximately $9,826,000. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold 6,543 shares of company stock worth $845,628 over the last 90 days. 4.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

JAZZ has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their price objective for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Piper Sandler reaffirmed an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Royal Bank of Canada reduced their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $184.00.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded up $2.33 on Friday, reaching $111.13. The company's stock had a trading volume of 726,472 shares, compared to its average volume of 836,816. Jazz Pharmaceuticals plc has a 52-week low of $95.49 and a 52-week high of $148.06. The stock has a market capitalization of $6.85 billion, a P/E ratio of 15.65, a PEG ratio of 1.04 and a beta of 0.33. The stock's 50-day moving average is $108.09 and its two-hundred day moving average is $121.01. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same period in the prior year, the company earned $2.68 earnings per share. The firm's revenue was down .5% on a year-over-year basis. As a group, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.